Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS – Free Report) – Research analysts at HC Wainwright upped their FY2026 earnings per share (EPS) estimates for Compass Pathways in a research note issued to investors on Monday, November 9th. HC Wainwright analyst P. Trucchio now expects that the company will earn ($1.40) per share for the year, up from their prior forecast of ($1.58). HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for Compass Pathways’ current full-year earnings is ($0.78) per share. HC Wainwright also issued estimates for Compass Pathways’ Q4 2026 earnings at ($0.38) EPS, Q1 2027 earnings at ($0.31) EPS, Q2 2027 earnings at ($0.31) EPS, Q3 2027 earnings at ($0.29) EPS, Q4 2027 earnings at ($0.25) EPS and FY2027 earnings at ($1.17) EPS.
A number of other brokerages have also issued reports on CMPS. Jefferies Financial Group reaffirmed a “buy” rating on shares of Compass Pathways in a report on Monday. B. Riley Financial boosted their target price on shares of Compass Pathways from $17.00 to $22.00 and gave the stock a “buy” rating in a report on Thursday, August 6th. Morgan Stanley boosted their target price on shares of Compass Pathways from $17.00 to $18.00 and gave the stock an “overweight” rating in a report on Thursday, August 6th. Weiss Ratings restated a “sell (d-)” rating on shares of Compass Pathways in a research report on Thursday, October 15th. Finally, Oppenheimer reaffirmed an “outperform” rating and set a $20.00 target price on shares of Compass Pathways in a research note on Tuesday, November 3rd. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $23.14.
Compass Pathways Stock Down 1.9%
NASDAQ CMPS opened at $9.12 on Wednesday. The stock’s 50 day moving average is $11.98 and its 200 day moving average is $10.45. The company has a current ratio of 1.50, a quick ratio of 1.50 and a debt-to-equity ratio of 0.35. Compass Pathways has a 12 month low of $4.88 and a 12 month high of $15.87. The stock has a market cap of $1.29 billion, a PE ratio of -2.61 and a beta of 2.43.
Compass Pathways (NASDAQ:CMPS – Get Free Report) last released its earnings results on Tuesday, November 3rd. The company reported ($0.31) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.39) by $0.08.
Institutional Investors Weigh In On Compass Pathways
A number of hedge funds have recently made changes to their positions in CMPS. Vivo Capital LLC purchased a new position in Compass Pathways during the 1st quarter valued at approximately $1,106,000. Seven Fleet Capital Management LP increased its stake in Compass Pathways by 295.1% in the 1st quarter. Seven Fleet Capital Management LP now owns 158,021 shares of the company’s stock worth $874,000 after acquiring an additional 118,021 shares during the last quarter. Orbimed Advisors LLC bought a new stake in Compass Pathways in the 1st quarter worth approximately $6,363,000. Eversept Partners LP purchased a new stake in shares of Compass Pathways during the 1st quarter worth approximately $3,749,000. Finally, Eagle Health Investments LP raised its holdings in shares of Compass Pathways by 35.6% during the 1st quarter. Eagle Health Investments LP now owns 2,060,427 shares of the company’s stock worth $11,394,000 after acquiring an additional 541,039 shares in the last quarter. 46.19% of the stock is currently owned by hedge funds and other institutional investors.
Latest Compass Pathways News
These are some of the CMPS news items that stood out recently:
- Positive Sentiment: A recent valuation analysis says CMPS could be 62% undervalued, arguing that the company’s FDA filing strengthens its investment case. The estimate may support investor optimism, but it reflects the analysis’s assumptions rather than a confirmed change in the company’s prospects. COMPASS Pathways Could Be 62% Undervalued As FDA Filing Sharpens The Case
- Positive Sentiment: HC Wainwright raised its EPS forecasts for Compass Pathways across 2026 and 2027, including improving its FY2027 estimate to a loss of $1.17 per share from a loss of $1.56. The revisions suggest the analyst expects losses to be narrower than previously forecast; HC Wainwright reiterated its Buy rating. HC Wainwright Reaffirms Buy Rating for Compass Pathways
- Neutral Sentiment: Management plans to attend the Jefferies Global Healthcare Conference on November 18–19, including a fireside chat and panel. The event could provide updates, but the announcement itself does not disclose new clinical or financial results. Compass Pathways to Participate in Jefferies Global Healthcare Conference
Compass Pathways Company Profile
Compass Pathways plc is a biotechnology company developing treatments for mental health conditions. Founded in 2016 by George Goldsmith and Ekaterina Malievskaia, the company is focused on advancing psychedelic-based therapies through clinical research. Its lead investigational product, COMP360, is a synthetic formulation of psilocybin being studied alongside psychological support. Compass is evaluating COMP360 primarily as a potential treatment for treatment-resistant depression and has also explored its use for other mental health conditions, including post-traumatic stress disorder.
Featured Articles
- Five stocks we like better than Compass Pathways
- Checkmate for AI Chips? NVIDIA’s Crisis Opens the Board
- Can NVIDIA Maintain Its Momentum Without Huang?
- Six Flags Lost $366 Million in Q3—Its Insiders Just Went Shopping
- What Went Wrong With Amprius Technologies’ Q3? Less Than You’d Think
Receive News & Ratings for Compass Pathways Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Compass Pathways and related companies with MarketBeat.com's FREE daily email newsletter.
